Articles

PRESS RELEASE: Interim Analysis Shows At Least 90% Chance of Statistically Significant Difference in PTSD Symptoms after MDMA-assisted Psychotherapy

PRESS RELEASE: Interim Analysis Shows At Least 90% Chance of Statistically Significant Difference in PTSD Symptoms after MDMA-assisted Psychotherapy

An interim analysis of data from the first of MAPs’ two Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder revealed a 90% or greater probability that the trial…

Conversations: Payton Nyquvest

Conversations: Payton Nyquvest

Numinus CEO Payton Nyquvest sat down with Report on Psychedelics to share his personal experience managing health issues, Numinus’s expansion plans, financing, and public offering. Click here to…

Business gets ready to trip: How psychedelic drugs may revolutionize mental health care

Business gets ready to trip: How psychedelic drugs may revolutionize mental health care

Fortune Magazine talks with American entrepreneur, author, and podcaster Tim Ferriss about the resurgence of interest in psychedelic therapy and why he’s donating $3 million to further research.Click…

Are Investors Ready To Change Their Minds About Psychedelic Drugs?

Are Investors Ready To Change Their Minds About Psychedelic Drugs?

An accessible article from Forbes details the similarities and differences between psychedelic drugs and cannabis and the opportunity for both investors and those looking for a new approach to…

Study: Psilocybin From Magic Mushrooms Plus Therapy Delivers Benefits Nearly Five Years Later

Study: Psilocybin From Magic Mushrooms Plus Therapy Delivers Benefits Nearly Five Years Later

A recent study into the effectiveness of psilocybin, combined with psychotherapy, in treating anxiety and depression reports that 60-80% of participants met criteria for clinically significant…

Roadmaps to Regulation: MDMA

Roadmaps to Regulation: MDMA

A report and policy proposal from the Beckley Foundation outlines how any risks inherent to MDMA could be more effectively mitigated within a legally regulated market. The report also highlights…

Investors hope psychedelics are the new cannabis. Are they high?

Investors hope psychedelics are the new cannabis. Are they high?

The Economist explores the increase in investment in the psychedelic assisted therapy space in this article. Click here to read the full article (subscription required).